Publications by authors named "L Perez-Lamas"
Article Synopsis
- * Out of these patients, 8 experienced treatment intolerance with asciminib while 11 developed resistance; treatment strategies included dose adjustments of cTKIs or considering ponatinib despite previous non-candidacy.
- * The overall survival rate was 73% with the best outcomes for those intolerant to drugs (100%), while patients who progressed to advanced stages had a notably low survival rate (25%).
Article Synopsis
- - New treatments are urgently needed for chronic myeloid leukemia (CML) to improve successful treatment discontinuations, with anti-PD-L1 checkpoint inhibitors showing promise due to increased levels in CML patients.
- - A phase Ib/II trial evaluated the safety of the anti-PD-L1 antibody atezolizumab combined with bosutinib in newly diagnosed CML patients, but was terminated early due to safety concerns after only 9 patients were enrolled.
- - The trial reported 44 adverse events, primarily gastrointestinal issues, with significant hepatotoxicity noted, including serious liver function test increases, leading to the conclusion that this drug combination should not be pursued in future studies.
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma.
Expert Opin Emerg Drugs
December 2023
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. Recent advances in immunotherapy such as chimeric antigen receptor T-cell therapy have significantly improved the outcomes in patients. Despite those advances, disease still recurs in many patients after multiple lines of therapy, and they eventually die.
View Article and Find Full Text PDFArticle Synopsis
- - The study focuses on the effectiveness of COVID-19 vaccination in individuals with oncohematological diseases (OHD) who received hematopoietic stem cell transplants (HSCT), addressing significant morbidity and mortality rates prior to vaccination.
- - It was found that these individuals maintained low but protective levels of neutralizing antibodies against SARS-CoV-2 after undergoing HSCT, indicating some persistent immune protection despite B-cell deficiencies.
- - Results showed that although cellular immunity was impaired in those who had allogeneic HSCT, infections that occurred post-transplant were mild, reinforcing the necessity and safety of COVID-19 vaccination for this vulnerable group.
(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs.
View Article and Find Full Text PDF